Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q53H76

UPID:
PLA1A_HUMAN

ALTERNATIVE NAMES:
Phosphatidylserine-specific phospholipase A1

ALTERNATIVE UPACC:
Q53H76; B2R8V2; B4DXA2; O95991; Q86WX6; Q9UPD2

BACKGROUND:
The enzyme Phospholipase A1 member A, with its alternative name Phosphatidylserine-specific phospholipase A1, exhibits specific lysophospholipase activity, particularly hydrolyzing lyso-PS but not PS. Its unique activity towards phosphatidylserines, especially those on apoptotic cells, underscores its selective role in cellular processes such as phospholipid remodeling and the immune response through the production of 2-acyl-1-lysophosphatidylserines.

THERAPEUTIC SIGNIFICANCE:
The exploration of Phospholipase A1 member A's function offers a promising avenue for the development of novel therapeutic approaches, targeting diseases where phospholipid metabolism and immune response modulation play a significant role.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.